AI Article Synopsis
- A study evaluated the effectiveness of hypomethylating agents (HMAs) in 172 adult MDS patients who underwent stem cell transplantation from 2000 to 2016.
- The patients were split into three groups based on their pre-transplant blast counts and HMA usage, showing significant differences in one-year survival and relapse rates among the groups.
- Results indicated that while survival rates were similar across groups, those with higher pre-transplant blast counts who received HMAs had a notably higher relapse rate, suggesting a link to chemotherapy-resistant disease.
Article Abstract
Information on the use of hypomethylating agents (HMAs) as a pre-transplant cytoreductive therapy in MDS is limited. We retrospectively evaluated outcomes of 172 adult MDS patients, who underwent allogeneic hematopoietic stem cell transplantation between January 2000 and December 2016. Patients were divided into three groups: group 1 - pre-transplant blasts <5% with HMA ( = 42), group 2 - pre-transplant blasts ≥5% with HMA ( = 38), group 3 - no HMA ( = 92). With a median follow up of 4.08 years, 1-year survival and relapse rates for groups 1, 2, and 3 were 75%, 40.2%, and 60.71%, respectively; and 17.6%, 26.6%, and 9.8%, respectively. Multivariate analysis revealed adverse relapse (HR 3.54; = .03) in group 2 compared to groups 1 and 3, while no difference in overall survival was noticed. Our study shows no survival association with pre-transplant HMA; although, higher relapse rate was observed in the non-responding patients indicating possible chemotherapy resistant disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865062 | PMC |
| http://dx.doi.org/10.1080/10428194.2019.1605070 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!